Assess comorbid depression and anxiety in glioblastoma patients.
Management
Consider antidepressant therapy for management of depressive symptoms in glioblastoma patients.
Account for antidepressant class when evaluating potential survival impact.
Continue standard glioblastoma treatment including maximal safe resection, radiotherapy, and chemotherapy.
Monitoring & Follow-up
Monitor depressive symptoms and antidepressant adherence.
Track survival outcomes while considering antidepressant exposure as a time-varying factor.
Risks
Potential for antidepressant therapy to have variable effects on survival; some studies suggest worsened survival with certain antidepressants.
High heterogeneity and inconclusive evidence necessitate cautious interpretation.
Patient & Prescribing Data
Adult glioblastoma patients with documented antidepressant use post-diagnosis
Antidepressant usage categorized into SSRIs, SNRIs, serotonin modulators, TCAs, and atypical antidepressants; survival impact varies and requires adjustment for molecular and socioeconomic factors.
Clinical Best Practices
Use multivariate Cox regression with time-varying covariates to assess antidepressant impact on survival, controlling for demographic, molecular, socioeconomic, and treatment variables.
Incorporate socioeconomic indices such as Area Deprivation Index and rural-urban classification in survival analyses.
Recognize the high prevalence of depression in glioblastoma and address it to potentially improve quality of life and treatment adherence.
